# US 2019/0167736 A1 · Bacteriophage for treating staphylococcus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167736 A1
- Document ID: US20190167736A1
- Status: Published application
- Kind: A1
- Application number: 15/746,663
- Filed: 2016-07-25
- Published: 2019-06-06
- Earliest claimed: 2015-07-23
- Assignees: Enbiotix, Inc.
- Applicants: Enbiotix, Inc.
- Inventors: Daniel J. FERULLO; Jeffrey A. RADDING
- Web page: https://patentgrep.com/patent/US20190167736A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1729: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/1767: {from invertebrates}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/48: acting on peptide bonds (3.4)
- A61P 31/04: Antibacterial agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/14: Streptococcus; Staphylococcus
- C12Y 302/01017: Lysozyme (3.2.1.17)
- C12Y 302/01052: Beta-N-acetylhexosaminidase (3.2.1.52)
- C12Y 304/24075: Lysostaphin (3.4.24.75)
- C12N 2795/10221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12Q 1/689: for bacteria
- G01N 2333/31: from Staphylococcus (G)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to GRCS bacteriophages, as well as to methods and compositions for the treatment of prosthetic joint infection. Particularly, the present invention provides bacteriophages specific against Staphylococcus aureus from prosthetic joint infections.

## Claims

### Claim 1

A method for treating prosthetic joint infection involving Staphylococcus aureus, comprising administering to the infected area and/or surface of the prosthetic a GRCS bacteriophage or a Podoviridae bacteriophage having a minor tail protein encoded by GRCS bacteriophage gene 18505614, or a functional derivative thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the functional derivative comprises an amino acid sequence having at least 70% identity with the minor tail protein encoded by GRCS bacteriophage gene 18505614.

### Claim 3 (depends on 1)

The method of claim 1, wherein the minor tail protein or the functional derivative thereof recognizes a surface determinant on Staphylococcus aureus.

### Claim 4 (depends on 1)

The method of claim 1, wherein the prosthetic joint infection is a mixed infection comprising one or more additional microbial strains.

### Claim 5 (depends on 4)

The method of claim 4, wherein the additional microbial strain is Gram-positive or Gram-negative.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the bacteriophage eliminates the Staphylococcus aureus.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the bacteriophage comprises a nucleic acid encoding a biofilm-degrading enzyme.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the bacteriophage comprises a nucleic acid encoding at least one antimicrobial polypeptide.

### Claim at position 12

-18. (canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the bacteriophage comprises a nucleic acid encoding at least one agent that inhibits an antibiotic resistance gene and/or a cell survival repair gene.

### Claim 20 (depends on 1)

The method of claim 1, wherein the bacteriophage comprises a nucleic acid encoding at least one repressor of a SOS response gene and/or bacterial defense gene.

### Claim at position 15

-23. (canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the bacteriophage comprises a nucleic acid encoding at least one agent which increases the susceptibility of a bacteria cell to an antimicrobial agent.

### Claim at position 17

-27. (canceled)

### Claim 28

An engineered bacteriophage comprising a minor tail protein as encoded by GRCS bacteriophage gene 18505614, or a functional derivative thereof,
wherein the minor tail protein or the functional derivative thereof, recognizes a surface determinant on Staphylococcus aureus associated with prosthetic joint infection.

### Claim 29 (depends on 28)

The bacteriophage of claim 28, wherein the bacteriophage is engineered to comprise a nucleic acid encoding a biofilm-degrading enzyme.

### Claim 30

(canceled)

### Claim 31 (depends on 28)

The bacteriophage of claim 28, wherein the bacteriophage is engineered to comprise a nucleic acid encoding at least one antimicrobial polypeptide.

### Claim at position 22

-38. (canceled)

### Claim 39 (depends on 28)

The bacteriophage of claim 28, wherein the bacteriophage is engineered to comprise a nucleic acid encoding at least one agent that inhibits an antibiotic resistance gene and/or a cell survival repair gene.

### Claim 40 (depends on 28)

The bacteriophage of claim 28, wherein the bacteriophage is engineered to comprise a nucleic acid encoding at least one repressor of a SOS response gene and/or bacterial defense gene.

### Claim at position 25

-43. (canceled)

### Claim 44 (depends on 28)

The bacteriophage of claim 28, wherein the bacteriophage is engineered to comprise a nucleic acid encoding at least one agent which increases the susceptibility of a bacteria cell to an antimicrobial agent.

### Claim at position 27

-52. (canceled)

### Claim 53 (depends on 28)

A pharmaceutical composition comprising a bacteriophage of claim 28, and a pharmaceutically acceptable carrier.

### Claim 54 (depends on 53)

The pharmaceutical composition of claim 53, wherein the pharmaceutical composition eliminates Staphylococcus aureus associated with the prosthetic joint infection.

### Claim 55 (depends on 53)

The pharmaceutical composition of claim 53, wherein the pharmaceutical composition removes biofilms associated with the prosthetic joint infection.

### Claim at position 31

-68. (canceled)
